Stay updated on Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial
Sign up to get notified when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.

Latest updates to the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedMinor wording changes in the Publications section and a page revision label (Revision: v3.3.2) were added; these do not affect core study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedThe government funding status notice was removed from the page. This change shifts administrative content but does not modify the study details or results.SummaryDifference0.2%

- Check27 days agoChange DetectedTaiwan study sites were updated: Tainan City, Taiwan, 704 and 710 were removed and replaced with Tainan, Taiwan, 704 and 710.SummaryDifference0.0%

- Check34 days agoChange DetectedThe Study Details page for NCT03412773 appears the same in both screenshots, with no changes to the main study information.SummaryDifference0.2%

- Check48 days agoChange DetectedAdded detailed trial results and substudy information for the tislelizumab vs sorafenib study (RATIONALE-301), including endpoints, locations, and Japanese safety run-in; removed reference to the 2024-01-10 results submission page in favor of the updated results-centric content.SummaryDifference100%

- Check62 days agoChange DetectedUpdate includes a government operations notice and new version tag v3.2.0, replacing v3.1.0.SummaryDifference2%

Stay in the know with updates to Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.